Ceftobiprole medocaril sodium

Ceftobiprole medocaril

Zevtera (ceftobiprole medocaril) is a small molecule pharmaceutical. Ceftobiprole medocaril was first approved as Zevtera on 2024-04-03.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

No data

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

No data

Labels

FDA

EMA

Brand Name	Status	Last Update
zevtera	New Drug Application	2025-03-21

Indications

FDA

EMA

No data

Agency Specific

FDA

EMA

Expiration	Code
CEFTOBIPROLE MEDOCARIL SODIUM, ZEVTERA, BASILEA PHARM ALLSCH
2034-04-03	GAIN
2029-04-03	NCE

Patent Expiration

No data

ATC Codes

J: Antiinfectives for systemic use

— J01: Antibacterials for systemic use

— J01D: Other beta-lactam antibacterials in atc

— J01DI: Other cephalosporins and penems in atc

— J01DI01: Ceftobiprole medocaril

HCPCS

No data

Clinical

Clinical Trials

28 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

No data

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Infections	D007239	EFO_0000544	—	4	—	4	—	1	9
Communicable diseases	D003141	—	—	4	—	4	—	—	8
Pneumonia	D011014	EFO_0003106	J18	1	—	4	—	1	6
Staphylococcal skin infections	D013207	EFO_1001849	L00	4	—	2	—	—	6
Infectious skin diseases	D012874	—	—	4	—	2	—	—	6
Cellulitis	D002481	EFO_0003035	L03.90	4	—	2	—	—	6
Bacterial skin diseases	D017192	—	—	—	—	3	—	—	3
Bacteremia	D016470	EFO_0003033	R78.81	—	1	1	—	—	2
Skin diseases	D012871	—	L00-L99	—	—	2	—	—	2
Bacterial infections	D001424	—	A49	1	—	1	—	—	2

Show 9 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Cerebral ventriculitis	D058565	—	—	—	1	—	—	1	2
Meningitis	D008581	EFO_0000584	G03	—	1	—	—	—	1

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Streptococcal infections	D013290	EFO_1001476	—	4	—	—	—	—	4
Acremonium	D000164	—	—	1	—	—	—	1	2
Chronic kidney failure	D007676	EFO_0003884	N18.6	1	—	—	—	—	1
Obesity	D009765	EFO_0001073	E66.9	1	—	—	—	—	1
Drug resistance	D004351	—	Z16.30	1	—	—	—	—	1
Ventilator-associated pneumonia	D053717	EFO_1001865	J95.851	1	—	—	—	—	1
Drug interactions	D004347	—	—	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hemorrhage	D006470	MP_0001914	R58	—	—	—	—	1	1
Cerebral hemorrhage	D002543	—	—	—	—	—	—	1	1
Subarachnoid hemorrhage	D013345	EFO_0000713	I60	—	—	—	—	1	1
Drug monitoring	D016903	—	—	—	—	—	—	1	1
Pharmacokinetics	D010599	—	—	—	—	—	—	1	1
Renal insufficiency	D051437	—	N19	—	—	—	—	1	1
Liver failure	D017093	—	K72.9	—	—	—	—	1	1
Hepatic insufficiency	D048550	—	—	—	—	—	—	1	1
Immunosuppression therapy	D007165	—	—	—	—	—	—	1	1
Diabetic foot	D017719	EFO_1001459	—	—	—	—	—	1	1

Show 2 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Ceftobiprole medocaril
INN	ceftobiprole medocaril
Description	Ceftobiprole, sold under the brand name Zevtera among others, is a fifth-generation cephalosporin antibacterial used for the treatment of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia. It is marketed by Basilea Pharmaceutica under the brand names Zevtera and Mabelio. Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls. Ceftobiprole has high affinity for penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus strains and retains its activity against strains that express divergent mecA gene homologues (mecC or mecALGA251). Ceftobiprole also binds to penicillin-binding protein 2b in Streptococcus pneumoniae (penicillin-intermediate), to penicillin-binding protein 2x in Streptococcus pneumoniae (penicillin-resistant), and to penicillin-binding protein 5 in Enterococcus faecalis.
Classification	Small molecule
Drug class	antiviral (arildone derivatives); cephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\C3=C(C(=O)[O-])N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1.[Na+]